Core Viewpoint - The article highlights the emergence of a new model in elderly care services, exemplified by the Changzhe Care Home in Beijing, which aims to provide comprehensive, inclusive, and professional elderly care services to residents and the surrounding community [2][3]. Group 1: Facility Overview - The Changzhe Care Home is a community elderly care complex with six floors, featuring 125 furnished rooms and 300 beds, and includes various functional areas such as an elderly university, care services, a community canteen, and specialized care zones for dementia and disability [2]. - The facility is set to open in November 2024 and will offer sustainable care support to families and communities [2]. Group 2: Service Model - The care home is exploring a "1+3+N" service model, which consists of "1 platform" for integrated services, "3 major scenarios" (home, community, and institutional care), and "N services" that encompass comprehensive care [3][7]. - The goal is to create a regional smart elderly care service complex that integrates medical and nursing services, with a focus on education and training for caregivers [3]. Group 3: Technology Integration - A one-stop smart elderly care service platform will be established, utilizing SaaS technology and connecting various health monitoring devices to provide tailored services based on individual needs [7][9]. - The integration of smart technology aims to enhance service efficiency and quality, allowing elderly individuals to access services more conveniently [9]. Group 4: Workforce Development - Training for caregivers to effectively use smart systems and devices is a priority, as many current workers may struggle with technology [10]. - The care home aims to improve the caregiver-to-elderly ratio, allowing one caregiver to serve 6-8 elderly individuals, thereby reducing costs and increasing efficiency [12]. Group 5: Market Trends - The article predicts a rise in small-scale service providers, such as "couple teams," which will offer personalized and flexible services, complementing larger service groups [13][14]. - The industry is currently facing challenges related to product development and the need for services to be more tailored to the elderly population [15][16].

Group 1 - Lepu Medical announced that its subsidiary, Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for clinical trials of its self-developed injectable recombinant type A botulinum toxin [1] - The revenue composition for Lepu Medical in 2024 is projected to be 54.5% from medical devices, 28.8% from pharmaceuticals, and 16.7% from medical services and health management [1]

Core Viewpoint - Lepu Medical announced that its subsidiary, Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its self-developed recombinant type A botulinum toxin [1] Company Summary - The recombinant type A botulinum toxin is indicated for the temporary improvement of moderate to severe frown lines caused by the activity of the corrugator and/or depressor anguli oris muscles in adults aged 65 and below [1] - Botulinum toxin is widely used in the fields of facial and neck wrinkle removal and contour shaping, causing muscle relaxation and inhibiting gland secretion through its chemical denervation effects [1]

Core Viewpoint - Lepu Medical (300003) announced that its subsidiary, Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the clinical trial of its self-developed injectable recombinant type A botulinum toxin [1] Group 1 - The approval of the clinical trial application for injectable recombinant type A botulinum toxin (LPJT-099/DP) signifies the company's strong and efficient R&D capabilities in the dermatology field [1] - This development enriches the company's product portfolio in dermatology, enhancing its core competitiveness in this niche market [1] - The progress in this research project supports the company's long-term development in the consumer healthcare market [1]

Core Viewpoint - Lepu Medical (300003.SZ) has received approval from the National Medical Products Administration (NMPA) for its subsidiary Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd. to conduct clinical trials for its self-developed injectable recombinant type A botulinum toxin [1] Group 1 - The clinical trial application for the injectable recombinant type A botulinum toxin (LPJT-099/DP) has been approved, indicating progress in the company's research and development efforts [1] - The amino acid sequence of the company's injectable recombinant type A botulinum toxin is identical to that of Botox® and Xeomin®, suggesting a competitive edge in the market [1] - The product is developed using recombinant protein technology, which offers advantages such as low biological risk, high purity, low immunogenic risk, high production efficiency, and controllable capacity [1] Group 2 - The advancement of this project signifies the company's strong and efficient R&D capabilities in the dermatology field, enhancing its product portfolio in this sector [1] - This development is expected to strengthen the company's core competitiveness in the dermatology niche and support its long-term growth in the consumer healthcare market [1]

Core Viewpoint - Lepu Medical (300003) announced that its subsidiary Lepu Jiantang has received approval from the National Medical Products Administration for the clinical trial of its self-developed injectable recombinant type A botulinum toxin [1] Group 1: Company Developments - The clinical trial application for the injectable recombinant type A botulinum toxin (LPJT-099/DP) has been approved [1] - The drug is indicated for the temporary improvement of moderate to severe frown lines caused by the activity of the corrugator and/or depressor anguli oris muscles in adults aged 65 and below [1]

乐普医疗8月1日公告，公司子公司乐普健糖药业（重庆）有限公司收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，同意其开展注射用重组A型肉毒毒素（LPJT-099/DP）的临床试验。适 应症为暂时性改善65岁及65岁以下成年人因皱眉肌和/或降眉肌活动引起的中度至重度皱眉纹。上述在 研项目尚处于研发早期阶段，后续临床试验存在结果不确定性高、研 发投入大、临床试验周期长等特 点，药品存在临床试验失败的风险。 ...

Core Viewpoint - Lepu Medical (300003.SZ) announced that its subsidiary, Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its self-developed injectable recombinant type A botulinum toxin, indicating strong R&D capabilities in the dermatology field [2] Group 1 - The approved product has advantages such as low biological risk and high purity, enhancing the company's product portfolio in dermatology [2] - The development of this product is expected to strengthen the company's core competitiveness in the dermatology segment [2] - The project is still in the early stages of development, with high uncertainty regarding clinical trial outcomes, significant R&D investment, and long trial cycles [2]

Core Viewpoint - Lepu Medical's subsidiary, Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd., has received approval from the National Medical Products Administration for its self-developed injectable recombinant type A botulinum toxin, indicating a significant advancement in the company's dermatology product portfolio [1] Group 1 - The approved product is intended for the temporary improvement of moderate to severe frown lines caused by the activity of the corrugator and/or depressor anguli oris muscles in adults aged 65 and below [1] - The successful progress of this research project highlights the company's strong and efficient R&D capabilities in the dermatology field [1] - This development enriches the company's product layout in dermatology, enhancing its core competitiveness in this niche market [1] Group 2 - The new product is expected to support the company's long-term development in the consumer healthcare market [1]

证券代码：300003 证券简称：乐普医疗 公告编号：2025-063 乐普（北京）医疗器械股份有限公司 关于注射用重组 A 型肉毒毒素 获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称"公司"）于今日获悉，子 公司乐普健糖药业（重庆）有限公司（以下简称"乐普健糖"）自主研发的注射 用重组 A 型肉毒毒素收到国家药品监督管理局（NMPA）核准签发的《药物临床 试验批准通知书》，由乐普健糖申报的注射用重组 A 型肉毒毒素（LPJT-099/DP） 临床试验申请获得批准，现将有关详情公告如下： 一、产品信息 药物名称：LPJT-099/DP 注册分类：治疗用生物制品 2.4 类 申请事项：临床试验 申请人：乐普健糖药业（重庆）有限公司 受理号：CXSL2500427 适应症：暂时性改善 65 岁及 65 岁以下成年人因皱眉肌和/或降眉肌活动引 起的中度至重度皱眉纹。 二○二五年八月一日 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 5 月 28 日受理的注射用重组 ...